For the quarter ending 2025-12-31, INBP had $582K increase in cash & cash equivalents over the period. $593K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net (loss) income | -762 | 123 | 808 |
| Amortization of right-of-use assets | 253 | 250 | 951 |
| Depreciation and amortization | 78 | 77 | 318 |
| Stock based compensation | 42 | 49 | 185 |
| Allowance for (charge offs of) uncollectible accounts receivable, net | - | - | 19 |
| Loss on disposal of fixed assets | - | - | -4 |
| Change in deferred tax assets | -119 | 68 | 1,264 |
| Impairment charge on equipment | 0 | - | 28 |
| Other, net | 4 | 3 | -10 |
| Accounts receivable, net | -391 | -1,447 | 781 |
| Inventories | -2,106 | 1,107 | -1,882 |
| Other assets | 114 | 87 | 92 |
| Operating lease obligations | - | - | -945 |
| Security deposits and other assets | 0 | - | - |
| Accounts payable | -656 | 533 | -211 |
| Accrued expenses and other liabilities | -360 | 188 | -1,355 |
| Operating lease obligations | -246 | -243 | - |
| Net cash provided by operating activities | 617 | 1,301 | 2,065 |
| Purchase of property and equipment | 24 | 173 | 191 |
| Purchase portion of right of use asset - financed | - | - | 14 |
| Net cash used in investing activities | -24 | -173 | -205 |
| Proceeds from exercise of employee stock options | 0 | - | 86 |
| Repayments under finance lease obligations | 11 | 11 | 8 |
| Net cash provided by (used in) financing activities | -11 | -11 | 78 |
| Net increase in cash | 582 | 1,117 | 1,938 |
| Cash and cash equivalents at beginning of period | 4,732 | 3,615 | 1,677 |
| Cash and cash equivalents at end of period | 5,314 | 4,732 | 3,615 |
INTEGRATED BIOPHARMA INC (INBP)
INTEGRATED BIOPHARMA INC (INBP)